Abstract
Pertussis or whooping cough has been given many names over the centuries. It was first recognized in the Middle Ages and since then various epidemics have been described. Jules Bordet and Octave Gengou isolated Bordetella pertussis, a causative agent for whooping cough, in Paris more than 100 years ago, which created an excellent opportunity to invent a vaccine. In 1914 the whole-cell pertussis vaccine was invented, then in the 1940s it was combined with tetanus and diphtheria toxoids to become DTP and it became widely available. A successive decrease in the incidence of the disease has since been observed. The vaccine has been about 80 % effective in preventing serious disease and death from pertussis. The disadvantage is that the vaccine offers protection for 5–10 years after the last dose of the full vaccination course. The second issue is the question of how to prevent side effects of the whole-cell vaccine. In the 1990s, the acellular vaccine was introduced in the US and gradually replaced the whole-cell vaccine. About 10 years later, a possible failure with the new vaccine has been observed, that is a lack of long-term protection. Nowadays, both vaccines are used, with the acellular vaccine being vastly predominant in most developed countries. Pertussis incidence has increased since the 1980s, but new prevention strategies include booster doses for specific age groups.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ACIP (1992) Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use – Supplementary ACIP statement recommendations of the immunization practices advisory committee. MMRW Rec Rep Feb. 07, 1992/41 (RR-1); 1–10. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00041801.htm. Accessed on 5 Feb 2016
ACIP (1997) Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP) MMRW Rec and Rep March 28, 1997/46 (RR-7); 1–25. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00048610.htm. Accessed on 5 Feb 2016
Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N (2009) First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine 27:6034–6041
Bouchez V, Hegerle N, Strati F, Njamkepo E, Guiso N (2015) New data on vaccine antigen deficient Bordetella pertussis isolates. Vaccine 14:751–770
Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV, Advisory Committee on Immunization Practices (ACIP) (2006) Advisory Committee on Immunization Practices (ACIP) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-3):1–34
Cherry JD (2010) The present and future control of pertussis. Clin Infect Dis 51(6):663–667
Cherry JD, Brunnel PA, Golden GS, Karzon DT (1988) Report of the task force on pertussis and pertussis immunization – 1988. Pediatrics 81:933–984
Dauer CC (1943) Reported whooping cough morbidity and mortality in the United States. Public Health Rep 58:661–676
ECDC (2014) European Center for Disease Prevention and Control. Annual epidemiological report 2014 – vaccine-preventable diseases. Available from: http://ecdc.europa.eu/en/publications/Publications/AER-2014-VPD-FINAL.pdf. Accessed on 5 Feb 2016
Guiso N (2014) Bordetella pertussis: why is it still circulating? J Infect 68:S119–S124
Gustafsson L, Hessel L, Storsaeter J, Olin P (2006) Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118:978–984
Klein NP (2014) Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother 10:2684–2690
Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R (2013) Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 131:e1716–e1722
Lynfield R, Schaffner W (2014) Can we conquer coqueluche? J Infect Dis 209(Suppl 1):S1–S3. doi:10.1093/infdis/jit487
Miranda C, Porte L, García P (2012) Bordetella holmesii in nasopharyngeal samples from Chilean patients with suspected Bordetella pertussis infection. J Clin Microbiol 50:1505
Morgan LG (1997) Pertussis immunization: an update. J Can Chiropr Assoc 41(2):86–90
Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J (2003) Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21:2015–2021
Romanus V, Jonsell R, Bergquist SO (1987) Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 6:364–671
Rucker WC (1912) Whooping cough, its nature and prevention: a popular discussion of a widespread and dangerous disease for which familiarity has bred. Contempt Public Health Rep 27:1736–1739
Sato Y, Sato H (1999) Development of acellular pertussis vaccines. Biologicals 27:61–69
Sheridan SL, Ware R, Grimwood K, Lambert SB (2012) Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 308:454–456
Tan T, Dalby T, Forsyth K, Halperin SA, Heininge U, Hozbor D, Plotkin S, Ulloa-Gutierrez R, von König CH (2015) Pertussis across the globe: recent epidemiologic trends from 2000–2013. Pediatr Infect Dis J 34:e222–e232
Weston R (2012) Whooping cough: a brief history to the 19th century. Can Bull Med Hist/Bulletin canadien d’histoire de la médecine 29:329–349
WHO/UNICEF (2015) Global immunization data. Available from: http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf?ua=. Accessed on 5 Feb 2016
Wood N, McIntyre P, Marshall H, Roberton D (2010) Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 29:209–215
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kuchar, E., Karlikowska-Skwarnik, M., Han, S., Nitsch-Osuch, A. (2016). Pertussis: History of the Disease and Current Prevention Failure. In: Pokorski, M. (eds) Pulmonary Dysfunction and Disease. Advances in Experimental Medicine and Biology(), vol 934. Springer, Cham. https://doi.org/10.1007/5584_2016_21
Download citation
DOI: https://doi.org/10.1007/5584_2016_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42009-7
Online ISBN: 978-3-319-42010-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)